| Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. S Redaelli, R Piazza, R Rostagno, V Magistroni, P Perini, M Marega, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 517 | 2008 |
| In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells M Puttini, AML Coluccia, F Boschelli, L Cleris, E Marchesi, ... Cancer research 66 (23), 11314-11322, 2006 | 468 | 2006 |
| Recurrent SETBP1 mutations in atypical chronic myeloid leukemia R Piazza, S Valletta, N Winkelmann, S Redaelli, R Spinelli, A Pirola, ... Nature genetics 45 (1), 18-24, 2013 | 419 | 2013 |
| Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients C Gambacorti Passerini, F Farina, A Stasia, S Redaelli, M Ceccon, ... Journal of the National Cancer Institute 106 (2), djt378, 2014 | 303 | 2014 |
| Bcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation AML Coluccia, A Vacca, M Dunach, L Mologni, S Redaelli, VH Bustos, ... The EMBO journal 26 (5), 1456-1466, 2007 | 286 | 2007 |
| A randomized prospective multicenter trial evaluating the platform-switching technique for the prevention of postrestorative crestal bone loss. L Prosper, S Redaelli, M Pasi, F Zarone, G Radaelli, EF Gherlone International Journal of Oral & Maxillofacial Implants 24 (2), 2009 | 247 | 2009 |
| Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study S Mori, E Vagge, P Le Coutre, E Abruzzese, B Martino, E Pungolino, ... American journal of hematology 90 (10), 910-914, 2015 | 230 | 2015 |
| Recurrent ETNK1 mutations in atypical chronic myeloid leukemia CB Gambacorti-Passerini, C Donadoni, A Parmiani, A Pirola, S Redaelli, ... Blood, The Journal of the American Society of Hematology 125 (3), 499-503, 2015 | 125 | 2015 |
| Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors S Redaelli, L Mologni, R Rostagno, R Piazza, V Magistroni, M Ceccon, ... American journal of hematology 87 (11), E125, 2012 | 123 | 2012 |
| Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase L Mologni, S Redaelli, A Morandi, I Plaza-Menacho, ... Molecular and cellular endocrinology 377 (1-2), 1-6, 2013 | 109 | 2013 |
| The distribution of occlusal contacts in the intercuspal position and temporomandibular disorder R Ciancaglini, EF Gherlone, S Redaelli, G Radaelli Journal of oral rehabilitation 29 (11), 1082-1090, 2002 | 95 | 2002 |
| Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer S Redaelli, M Ceccon, M Zappa, GG Sharma, C Mastini, M Mauri, ... Cancer research 78 (24), 6866-6880, 2018 | 92 | 2018 |
| Four-year follow-up of larger-diameter implants placed in fresh extraction sockets using a resorbable membrane or a resorbable alloplastic material. L Prosper, EF Gherlone, S Redaelli, M Quaranta International Journal of Oral & Maxillofacial Implants 18 (6), 2003 | 84 | 2003 |
| SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub R Piazza, V Magistroni, S Redaelli, M Mauri, L Massimino, A Sessa, ... Nature communications 9 (1), 2192, 2018 | 72 | 2018 |
| Inhibition of RET tyrosine kinase by SU5416 L Mologni, E Sala, S Cazzaniga, R Rostagno, T Kuoni, M Puttini, J Bain, ... Journal of Molecular Endocrinology 37 (2), 199-212, 2006 | 70 | 2006 |
| Regional blood acidification enhances extracorporeal carbon dioxide removal: a 48-hour animal study A Zanella, P Mangili, S Redaelli, V Scaravilli, M Giani, D Ferlicca, ... Anesthesiology 120 (2), 416-424, 2014 | 50 | 2014 |
| NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma A Galietta, RH Gunby, S Redaelli, P Stano, C Carniti, A Bachi, PW Tucker, ... Blood, The Journal of the American Society of Hematology 110 (7), 2600-2609, 2007 | 50 | 2007 |
| BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients M Marega, RG Piazza, A Pirola, S Redaelli, A Mogavero, I Iacobucci, ... Leukemia 24 (8), 1445-1449, 2010 | 48 | 2010 |
| Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling RH Gunby, S Ahmed, R Sottocornola, M Gasser, S Redaelli, L Mologni, ... Journal of medicinal chemistry 49 (19), 5759-5768, 2006 | 42 | 2006 |
| FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery R Piazza, A Pirola, R Spinelli, S Valletta, S Redaelli, V Magistroni, ... Nucleic acids research 40 (16), e123-e123, 2012 | 41 | 2012 |
